Wound Management Technologies, Inc. Announces Renewal of Sponsorship Agreement with PRESENT Podiatry and PRESENT Diabetes with Access to Nearly 10,000 Podiatrists and Podiatric Residents and Over 82,000 Diabetes Healthcare Professionals

Jan 25, 2010, 16:00 ET from Wound Management Technologies, Inc.

FORT WORTH, Texas, Jan. 25 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that its subsidiary, Wound Care Innovations, LLC, has renewed its agreement as a major sponsor for PRESENT Podiatry and as an educational sponsor for PRESENT Diabetes.  PRESENT e-Learning Systems is dedicated to improving the knowledge and skills of medical professionals throughout the world by providing high quality medical education programming via the Internet and by fostering collaboration with their peers at worldwide centers of excellence.  PRESENT Podiatry now publishes to over 9,000 podiatrists and 800 podiatric students with lecture views of over 62,000. PRESENT Diabetes now publishes to 82,394 diabetes healthcare professionals and in the month of December 2009, received 28,785 unique visitors.

In addition to this, the Mount Sinai School of Medicine, Harvard, and the University of Maryland are now using the PRESENT Mentor platform to train their internal medicine residents on diabetes. In the same way that PRESENT Podiatry has standardized the education of podiatric residents, PRESENT will shortly be rolling out an online educational curriculum for all internal medicine residents nationally.  

"We are excited about our continued relationship with PRESENT," states Cathy Bradshaw, President of Wound Care Innovations.  "They are committed to improving the knowledge and skills of medical professionals throughout the world by providing high quality medical education programs and work with the leaders in the field of clinical medicine. Podiatry and Diabetes is an important market segment for us as our advanced wound care collagen product, CellerateRx, has shown to be effective in the management of the difficult diabetic wounds.  In addition, our new independent reps are increasingly calling on podiatrists and we believe that our relationship with PRESENT will be an asset for them."

For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM - News), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene http://www.celgene.com, Geron http://www.geron.com, and Human Genome Sciences http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Further Information:

Shareholder Relations-Communications 954-357-0614


SOURCE Wound Management Technologies, Inc.



RELATED LINKS

http://www.woundmanagementtechnologies.com